Specialty Drug Updates

Cardiology Clinical Coverage

Specialty-focused drug approvals, safety updates, trial context, and clinical reference coverage for healthcare professionals.

Clinical Coverage

Search drug updates and clinical coverage.

12 loaded

Cardiology

FDA Approves Semaglutide for HFpEF: 20% Reduction in Heart Failure Events

Semaglutide approved for HFpEF: 20% reduction in heart failure events. Key implications for clinicians.

May 14|3 min read|Dr. Arjun Sharma

Cardiology

HFpEF Management 2026: SGLT2 Inhibitors and Spironolactone Show Mixed Results

HFpEF management updates: SGLT2 inhibitors show promise, while spironolactone lacks efficacy in recent trials.

May 14|3 min read|Dr. Kavya Sharma

Cardiology

Baxdrostat Reduces Resistant Hypertension: Comparison with Spironolactone and Eplerenone

Baxdrostat reduces resistant hypertension: 12 mmHg blood pressure reduction compared to spironolactone and eplerenone.

May 14|3 min read|Dr. Kavya Sharma

Cardiology

Baxdrostat Targets Aldosterone Pathway: New Algorithm for Resistant Hypertension Management

Baxdrostat targets aldosterone pathway for resistant hypertension: new algorithm shows 15 mmHg reduction in BP.

May 12|3 min read|Dr. Kavya Sharma

Cardiology

Enlicitide Reduces LDL Cholesterol Significantly in Phase 3 Trial

Enlicitide reduces LDL cholesterol by 47% in HeFH patients, offering a new oral PCSK9 inhibitor option.

May 7|3 min read|Dr. Arjun Sharma

Cardiology

FDA Approves Semaglutide for PAD: 13% Improvement in Walking Distance in STRIDE Trial

Semaglutide approved for PAD: 13% walking distance improvement in STRIDE trial. Learn more about the implications for treatment.

May 7|2 min read|Dr. Arjun Sharma

Cardiology

FDA Approves Semaglutide for HFpEF: 52% Improvement in Heart Failure Symptoms

Semaglutide improves heart failure symptoms by 52% in HFpEF patients, marking a significant advancement in treatment options.

May 6|3 min read|Dr. Arjun Sharma

Cardiology

FDA Approves Semaglutide for Peripheral Artery Disease: STRIDE Trial Shows Improved Walking Distance

FDA approves semaglutide for peripheral artery disease: 30% improvement in walking distance in STRIDE trial.

May 6|3 min read|Dr. Arjun Sharma

Cardiology

PCSK9 Inhibitors: Evolocumab, Alirocumab, and Inclisiran Reduce LDL-C by 50% in 2024 Guidelines

PCSK9 inhibitors evolocumab, alirocumab, and inclisiran reduce LDL-C by 50% in 2024 guidelines for ASCVD patients.

May 5|3 min read|Dr. Kavya Sharma

Cardiology

FDA Approves Enlicitide for LDL Cholesterol Reduction: 30% Decrease in Phase 3 Trial

FDA approves Enlicitide for LDL cholesterol reduction: 30% decrease in Phase 3 trial results.

May 5|3 min read|Dr. Arjun Sharma

Cardiology

FDA Approves Semaglutide for PAD: Improved Functional Outcomes in STRIDE Trial

Semaglutide improves functional outcomes in PAD: 35% walking ability increase in STRIDE trial.

May 3|3 min read|Dr. Kavya Sharma

Cardiology

FDA Approves Empagliflozin for HFpEF: 21% Reduction in CV Events

Empagliflozin approved for HFpEF: 21% CV event reduction in EMPEROR-Preserved trial.

May 2|3 min read|Dr. Arjun Sharma